CD274 and lung carcinoma: In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has made a breakthrough in the treatment of lung cancer, and several clinical studies have shown that patients with high levels of PD-L1 gene expression in tissues are better treated with anti-PD-1/PD-L1 inhibitors (32, 33).